

Pipeline Disclaimer

The following slide reflects the new molecular entities that comprise Eli Lilly and Company's development pipeline. Included is the lead indication for each molecule; excluded are earlier indications for pipeline molecules and new indications or line extensions of currently-marketed products. For competitive reasons, some pipeline molecules are not identified; instead, the therapeutic area in which the molecule is being evaluated is listed on the slide.

There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, or delayed, or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval, or that they will prove to be commercially successful.

Information on the following slide is current as of January 21, 2010. Lilly assumes no duty to update this information.

Abbreviations:

ASO: antisense oligonucleotide
BPH: benign prostatic hyperplasia
CRD: chronic renal disease
DLBCL: diffuse large b-cell lymphoma
DR: diabetic retinopathy
NHL: non-Hodgkin's lymphoma
NSCLC: non-small cell lung cancer
RA: rheumatoid arthritis

Other Information:

- A green or red arrow indicates a change since the last pipeline update.
- "Achieved milestone" means that first patient visit has occurred in a trial at the given phase or that a molecule has been submitted for regulatory review.
- "Attrition" means that a molecule is no longer in clinical development.
- There is no significance to the position a molecule occupies in a column or set of columns within a phase.


Lilly NME Pipeline

January 21, 2010

New Chemical Entity (NCE)
<i>New Biotech Entity (NBE)</i>

Movement since Dec 2009 update

- Achieved milestone
- Attrition
- New molecule



* in an ongoing Phase 2/3 trial